VERAXA Biotech Shifts Focus to Oncology Pipeline and Industrial Partnerships

VERAXA Biotech is making a strategic pivot to concentrate on its oncology pipeline and forge industrial partnerships for its technology platforms and products, following the completion of its business combination and the commencement of Nasdaq trading in June 2026. This move comes as Xlife Sciences AG, a Swiss incubator and accelerator, reported that VERAXA has secured a financing base to support its next development steps. Xlife Sciences also highlighted VERAXA's significance within its broader portfolio strategy. VERAXA, now trading under the ticker VRXA on Nasdaq, is dedicated to building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

In its first-half 2026 report, Xlife Sciences detailed operational and scientific progress across its portfolio, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI, and inflamed pharma. The portfolio comprises 416 patents and patent applications, including 216 granted intellectual property rights. For the second half of 2026, Xlife Sciences said it will continue supporting VERAXA in establishing industry partnerships while pursuing commercialization and further development across its portfolio. For more information on VERAXA, visit the company's newsroom at https://ibn.fm/VRXA. To view the full report, visit https://ibn.fm/LwLwP.

VERAXA's focus on oncology and industrial partnerships is poised to accelerate the development of its innovative antibody-based therapeutics, potentially bringing new treatment options to patients with high unmet medical needs. Xlife Sciences' continued support and the company's robust patent portfolio underscore a strong commitment to advancing life sciences innovations. As VERAXA progresses its pipeline and seeks industry collaborations, it may attract further investment and partnerships, driving growth and enhancing its market position. The completion of its business combination and Nasdaq listing provides a solid foundation for these efforts. For investors and industry observers, VERAXA's progress will be a key indicator of the potential for next-generation antibody therapeutics and the effectiveness of Xlife Sciences' incubator model in translating research into commercial success.